Correlation Engine 2.0
Clear Search sequence regions


  • ag490 (12)
  • angiogenesis (1)
  • common bile duct (1)
  • cytokines (1)
  • effect drug (1)
  • il 6 (1)
  • il6 (1)
  • JAK2 (1)
  • LBP (2)
  • LBP 6 (1)
  • liver (1)
  • liver fibrosis (2)
  • portal cirrhosis (1)
  • propranolol (12)
  • STAT3 (3)
  • western blot (2)
  • Sizes of these terms reflect their relevance to your search.

    AG490, the specific inhibitor of JAK2/STAT3 signaling, has been shown to decrease portal pressure, splanchnic hyperdynamic circulation and liver fibrosis in cirrhotic rats. Nonselective betablockers such as propranolol are the only drugs recommended in the treatment of portal hypertension. The aim of this study was to explore the combinative effect of treatment with propranolol and AG490 on portal hypertension. Rats induced by common bile duct ligation were treated with vehicle, AG490, propranolol, or AG490 + propranolol for 2 weeks. Hemodynamics parameters were assessed. Expressions of phospho-STAT3 protein and its down-regulated cytokines in splanchnic organs were detected by ELISA or western blot. Lipopolysaccharide binding protein (LBP) and IL-6 were assessed by ELISA or western blot. Characterization of liver and mesentery was performed by histological analyses. Highly expressed phospho-STAT3 protein in cirrhotic rats could successfully be inhibited by AG490 or AG490 + propranolol treatments but not by propranolol alone. Both AG490 and propranolol significantly reduced portal pressure and hyperdynamic splanchnic circulation, and combination of AG490 and propranolol achieved an additive effect than with either drug alone. AG490, alone or in combination with propranolol, inhibited liver fibrosis, splenomegaly and splanchnic angiogenesis. Increased markers of bacterial translocation (LBP and IL6) were greatly reduced by propranolol but not by AG490. The combination of propranolol and AG490 caused a greater improvement of portal hypertension and might therefore offer a potentially promising therapy in the portal hypertension treatment. © 2015 Journal of Gastroenterology and Hepatology Foundation and John Wiley & Sons Australia, Ltd.

    Citation

    Dong Wang, Qin Wang, Jikai Yin, Rui Dong, Qing Wang, Xilin Du, Jianguo Lu. Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis. Journal of gastroenterology and hepatology. 2016 May;31(5):1037-44


    PMID: 26487394

    View Full Text